These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 11014098)

  • 21. [Evidence-based treatment of methotrexate-resistant rheumatoid arthritis. Cytokine antagonists].
    Schnabel A; Gross WL
    Dtsch Med Wochenschr; 2003 Jan; 128(5):201-3. PubMed ID: 12557112
    [No Abstract]   [Full Text] [Related]  

  • 22. Anakinra: a review of its use in the management of rheumatoid arthritis.
    Waugh J; Perry CM
    BioDrugs; 2005; 19(3):189-202. PubMed ID: 15984903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monotonicity of interleukin-1 receptor-ligand binding with respect to antagonist in the presence of decoy receptor.
    Gnacadja G; Shoshitaishvili A; Gresser MJ; Varnum B; Balaban D; Durst M; Vezina C; Li Y
    J Theor Biol; 2007 Feb; 244(3):478-88. PubMed ID: 17011587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Proposed guidelines for the clinical evaluation of interleukin-1 inhibitors in the treatment of rheumatoid arthritis.
    Dougados M
    Eur Cytokine Netw; 1990; 1(4):235-7. PubMed ID: 2151768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anakinra for flares of pyogenic arthritis in PAPA syndrome.
    Dierselhuis MP; Frenkel J; Wulffraat NM; Boelens JJ
    Rheumatology (Oxford); 2005 Mar; 44(3):406-8. PubMed ID: 15637033
    [No Abstract]   [Full Text] [Related]  

  • 26. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.
    Cohen SB; Moreland LW; Cush JJ; Greenwald MW; Block S; Shergy WJ; Hanrahan PS; Kraishi MM; Patel A; Sun G; Bear MB;
    Ann Rheum Dis; 2004 Sep; 63(9):1062-8. PubMed ID: 15082469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The safety of interleukin-1 receptor antagonist (anakinra) in the treatment of rheumatoid arthritis].
    Riente L
    Reumatismo; 2004; 56(1 Suppl 1):74-9. PubMed ID: 15201943
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis.
    Tesser J; Fleischmann R; Dore R; Bennett R; Solinger A; Joh T; Modafferi D; Schechtman J;
    J Rheumatol; 2004 Apr; 31(4):649-54. PubMed ID: 15088288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin-I antagonists.
    Dower SK; Fanslow W; Jacobs C; Waugh S; Sims JE; Widmer MB
    Ther Immunol; 1994 Apr; 1(2):113-22. PubMed ID: 7584483
    [No Abstract]   [Full Text] [Related]  

  • 30. From the Food and Drug Administration.
    Schwetz BA
    JAMA; 2002 Jan; 287(1):33. PubMed ID: 11754690
    [No Abstract]   [Full Text] [Related]  

  • 31. Patient- versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapy.
    Cohen SB; Strand V; Aguilar D; Ofman JJ
    Rheumatology (Oxford); 2004 Jun; 43(6):704-11. PubMed ID: 14997006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful treatment of refractory Schnitzler syndrome with anakinra: comment on the article by Hawkins et al.
    Martinez-Taboada VM; Fontalba A; Blanco R; Fernández-Luna JL
    Arthritis Rheum; 2005 Jul; 52(7):2226-7. PubMed ID: 15986356
    [No Abstract]   [Full Text] [Related]  

  • 33. New-onset psoriasis following treatment with the interleukin-1 receptor antagonist anakinra.
    González-López MA; Martínez-Taboada VM; González-Vela MC; Fernández-Llaca H; Val-Bernal JF
    Br J Dermatol; 2008 May; 158(5):1146-8. PubMed ID: 18284383
    [No Abstract]   [Full Text] [Related]  

  • 34. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
    Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii2-ii12. PubMed ID: 15479866
    [No Abstract]   [Full Text] [Related]  

  • 35. Anakinra and its rapidly expanding role in management of nonarthritic systemic disorders.
    Kapoor S
    J Rheumatol; 2009 Feb; 36(2):446; author reply 447. PubMed ID: 19208574
    [No Abstract]   [Full Text] [Related]  

  • 36. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis.
    Dayer JM
    Rheumatology (Oxford); 2003 May; 42 Suppl 2():ii3-10. PubMed ID: 12817089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of interleukin-1 in bone resorption in rheumatoid arthritis.
    Strand V; Kavanaugh AF
    Rheumatology (Oxford); 2004 Jun; 43 Suppl 3():iii10-iii16. PubMed ID: 15150427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of anakinra on clinical and radiological outcomes in rheumatoid arthritis.
    Bresnihan B
    Ann Rheum Dis; 2002 Nov; 61 Suppl 2(Suppl 2):ii74-7. PubMed ID: 12379629
    [No Abstract]   [Full Text] [Related]  

  • 39. Anakinra: new preparation. Weakly effective in rheumatoid arthritis.
    Prescrire Int; 2004 Apr; 13(70):43-5. PubMed ID: 15148945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anakinra therapy in a child with systemic-onset juvenile rheumatoid arthritis after human herpesvirus 6 encephalitis.
    Mirkinson LJ; Nagle D; Kadom N; Jones OY
    J Clin Rheumatol; 2006 Apr; 12(2):83-6. PubMed ID: 16601542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.